HORIBA receives accolade for Best New Clinical Instrumentation of 2022 at special ceremony during 2023 AACC.

Glucose-6-phosphate dehydrogenase test kit from HORIBA group company Pointe Scientific, now distributed in UK by HORIBA.

The British In Vitro Diagnostic Association (BIVDA) today announced the appointment of Helen Dent as Interim Chief Executive Officer. Helen will replace outgoing CEO, Doris-Ann Williams, who has retired from her role. Helen will lead the organisation in championing the in vitro diagnostics (IVD) industry to politicians, policymakers, media and relevant stakeholders and in supporting members to improve patient outcomes. Helen, who will step into the role following over three years as Chief Operat...

Doris-Ann Williams has retired from her role as Chief Executive at BIVDA, after almost 22 years. Doris-Ann said, “I have been privileged to do a job I have loved representing the industry I am passionate about. It has been wonderful to see the value of diagnostics and laboratory medicine increase in profile in UK healthcare during the last 20 years, although there is still more to be done. I am now looking forward to starting a new chapter in my life and wish BIVDA continued success in the...

Dr Caroline Wilson, former principal scientist at the North East Innovation Lab, has been appointed to the role of commercial business manager.

The British In Vitro Diagnostics Association (BIVDA) has today launched a new independent whitepaper which examines the UK genomics landscape, with a focus on patient access to genomic testing.

The British In Vitro Diagnostics Association (BIVDA) commissioned the University of Nottingham to produce an independent White Paper examining the UK Government’s procurement of Covid-19 tests during the pandemic, which has been released today.

Digital clinical diagnostics and diabetes home testing provider Digostics and University Hospital Southampton NHS Foundation Trust (UHS) announced today a partnership that will see expectant mothers under the care of UHS maternity services become the first, anywhere in the world, to access ground-breaking new remote testing technology designed to improve screening for gestational diabetes mellitus (GDM).

Oxford Cancer Biomarkers Ltd (OCB), a leader in AI-driven, precision cancer diagnostics, has successfully closed its latest investment round.

Fast MDx is the first fully automated, high-throughput, near-patient testing system. It can detect many pathogens with unrivalled speed without the need for expensive biosecure laboratories. Developed by London-based social enterprise company Fast MDx, the eponymous testing system cuts the typical 24 to 48 hour waiting time to just one to two hours.